Vaccine against Middle East respiratory syndrome coronavirus

Affiliations

¹ College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
² Centre of Excellence in Bionanoscience Research, and Genomic and Biotechnology Research Group, Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
³ Department of Laboratory Medicine and Pathobiology, and Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada.
⁴ College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China; Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou, China. Electronic address: shenyy@scau.edu.cn.

Comment

Xuejuan Shen et al. Lancet Infect Dis. 2019 Oct.

. 2019 Oct;19(10):1053-1054.

doi: 10.1016/S1473-3099(19)30476-1.

¹ College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
² Centre of Excellence in Bionanoscience Research, and Genomic and Biotechnology Research Group, Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
³ Department of Laboratory Medicine and Pathobiology, and Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada.
⁴ College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China; Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou, China. Electronic address: shenyy@scau.edu.cn.

No abstract available

Comment on

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN. Modjarrad K, et al. Lancet Infect Dis. 2019 Sep;19(9):1013-1022. doi: 10.1016/S1473-3099(19)30266-X. Epub 2019 Jul 24. Lancet Infect Dis. 2019. PMID: 31351922 Free PMC article. Clinical Trial.

1. Modjarrad K, Roberts CC, Mills KT. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19:1013–1022. - PMC - PubMed
1. WHO WHO MERS global summary and assessment of risk. 2018. https://www.who.int/csr/disease/coronavirus_infections/risk-assessment-a...
1. Sabir JSM, Lam TTY, Ahmed MMM. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science. 2016;351:81–84. - PubMed
1. Reusken CB, Haagmans BL, Muller MA. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis. 2013;13:859–866. - PMC - PubMed
1. Haagmans BL, van den Brand JMA, Raj VS. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016;351:77–81. - PubMed